The Global Alzheimer’s Platform Foundation (GAP) thanks the First Lady for the grace and dignity she showed before and after President Carter’s term, and even more so these past six months after bravely announcing her dementia diagnosis. We join many around the world mourning her loss while acknowledging her quiet, positive impact over her 96 years.  […]

We applaud First Lady Jill Biden and the White House Gender Policy Council on the first ever initiative on Women’s Health Research, with a focus on ‘engaging the scientific, private sector, and philanthropic communities’. GAP is committed to ensuring that clinical research includes all people, and that includes ensuring that women are equally represented. We […]

Today, the US Senate confirmed President Biden’s nominee for National Institutes of Health (NIH) Director, Monica Bertagnolli, MD, who will lead the country’s top medical research institute. “We are thrilled that the US Senate has confirmed Dr. Monica Bertagnolli as the new Director of the NIH, as she is an esteemed leader with an impressive career […]

Revolutionary Studies, Record Breaking Collaboration, and Promising News on Biomarker Studies Top the Charts at AAIC   Washington D.C., Aug 31, 2023— Researchers and leaders from the Global Alzheimer’s Platform Foundation® (GAP) assembled with the world’s leading Alzheimer’s researchers, patient advocates, and clinicians at the annual Alzheimer’s Association International Conference (AAIC). From the memorable week, […]

Jessica Cantu from GAP-Net site El Faro Health and Therapeutics was at the Alzheimer’s Association’s International Conference (AAIC) in Amsterdam and spoke about the creation of the site in Starr County, Texas. En el condado Starr, casi uno en cada cuatro adultos de 65 años de edad en adelante fueron diagnosticados con Alzheimer en el […]

The FDA’s approval comes following the recommendation of an FDA advisory committee, which voted unanimously for Leqembi’s full approval earlier this month WASHINGTON, DC, July 6, 2023 — Following a decision from the U.S. Food and Drug Administration (FDA) granting full traditional approval to Leqembi, a disease-modifying Alzheimer’s treatment from Eisai, Global Alzheimer’s Platform Foundation® (GAP) […]

GAP Community Connector, Paula Atkinson, was a guest writer for the Orlando Times and explained why she and GAP are committed to advancing Alzheimer’s clinical research in Black and Brown communities. My grandmother was treated for Alzheimer’s disease, but never diagnosed with it. Why? She was toldby her doctor that it would take too long […]

GAP-Net Site Kerwin Medical Center was featured in Community Impact on the rate of Alzheimer’s disease in Hispanic communities, and how they can help. As part of a nationwide study, Kerwin Medical Center is testing the efficacy of Aducanumab, a drug that helps a type of plaque in the brain and slows memory impairment caused […]

GAP-Net Site K2 Medical Research was featured in the Orlando Times speaking about the rate of Alzheimer’s in the black community, and studies they have that can help. ORLANDO – For the 580,000 Floridians who are living with Alzheimer’s disease, or for the state’s 1.1 million citizens who who serve as unpaid Alzheimer’s caregivers, one […]

GAP President John Dwyer was quoted in the Financial Times talking about how the CMS decision will limit patient access to possible life saving Alzheimer’s treatments. Eisai has warned that mandatory data collection by US health authorities could restrictpatient access to the Japanese drugmaker’s new Alzheimer’s treatment. The company said a decision by Centers for […]

Bio-Hermes won’t just change Alzheimer’s research and diagnostics. It has the potential to save and change lives. WASHINGTON, DC (June 14, 2023) — Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET […]

Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 12) – “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of […]

June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a […]

GAP President John Dwyer was featured in McKnights Senior Living on the CMS decision to support only traditionally FDA-approved drugs. A Thursday announcement by the Centers for Medicare & Medicaid Services regarding coverage of Alzheimer’s drugs is being met with skepticism by some industry advocates who say that “the devil is in the details.” CMS […]

GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]

News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers […]

Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]

GAP-Net Site The Alzheimer’s Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer’s Disease  Research Center of Albany is looking for volunteers for an Alzheimer’s clinical study, putting an emphasis on the recruitment of people of color.  While people from underrepresented communities — including those who are […]

2022 Citizen Scientist Champion Award Elevated Honoree, Bob Deady, was featured in the KU ADRC publication for his dedication to Alzheimer’s research. There’s a familiar face around the University of Kansas Alzheimer’s Disease Research Center (KU ARDC). He doesn’t have an office, or a nameplate on the door or letters behind his name. But he’s doing his […]

GAP President John Dwyer wrote an op-ed in the Dallas Examiner calling on President Biden to reverse the Centers for Medicare and Medicaid Services to cover Leqembi and future Alzheimer’s drugs and treatments. The Biden administration has a big problem on its hands. It’s sending mixed signals on new Food and Drug Administration approved Alzheimer’s […]

The Global Alzheimer’s Platform Foundation® adds Lammert Albers to its team in the role of chief commercial officer; he joins GAP with leadership experience in growing clinical trial and life science technology companies WASHINGTON, DC (Feb. 21, 2023) — The Global Alzheimer’s Platform Foundation (GAP) welcomes Lammert Albers to its leadership team. Lammert has successfully […]

“With this approval, it is incumbent on Center for Medicare and Medicaid Services (CMS) Administrator Chiquita Brooks-LaSure and the drug’s sponsors to offer this life-changing therapy to patients quickly, while prioritizing access and economic fairness.” Statement attributed to Global Alzheimer’s Platform Foundation President John Dwyer: Washington, D.C. (Jan. 6, 2023) — We applaud the Food […]

GAP Associate Director of Recruitment & Strategic Initiatives, Dr. Tamiko MaGee Rodgers, was featured on the Roland Martin Unfiltered Daily Digital Show and spoke about Alzheimer’s disease clinical trials.

Washington, D.C. (Nov. 30, 2022) – “Following the positive, detailed results from Eisai on lecanemab, a monoclonal antibody therapy for the treatment of Alzheimer’s, there is every reason for the Alzheimer’s community to have optimism today. Thanks to the unwavering commitment of Eisai, its clinical trial partners, and most importantly, the people who participated in […]